This activity was originally broadcast in conjunction with AMCP 2025.
Program Description
Hypertrophic cardiomyopathy (HCM) is a complex heart condition that is often underdiagnosed, leading to inadequate treatment and causing a significant health care burden. New treatments, such as cardiac myosin inhibitors, target the underlying causes of HCM and offer symptom relief to patients. Managed care providers must be familiar with these new therapies to facilitate access and improve clinical outcomes. This program will explore the inclusion of cardiac myosin inhibitors within updated guidelines for managing HCM and the challenges and limitations of conventional therapeutic approaches. Beyond pharmacological management strategies, managed care professionals will review and discuss data-driven models for reducing health-related complications and burdens associated with HCM.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 9, 2025
Expiration date: April 9, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the prevalence of hypertrophic cardiomyopathy (HCM) and the clinical and economic burden of disease.
- Identify the pathophysiological targets of current therapies used in the management of HCM.
- Analyze the current treatment guidelines for HCM and the recent clinical trial data for new and emerging agents.
- Investigate managed care strategies that support evidence-based treatment in HCM that consider patient-specific factors, clinical guidelines, cost-effectiveness, and health equity principles within a collaborative care model.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
